TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX:ASP) is proud to announce its support of the distribution of the new Men’s Health Guidelines for Family Medicine. These Guidelines, developed by an independent body of family physicians, specialists, pharmacists and other health professionals, along with the Canadian Society for the Study of the Aging Male (CSSAM), are designed to meet the needs of family physicians managing common health issues confronting men over the age of 40.
The Guidelines, for a limited time, will be distributed free-of-charge to licensed family physicians across Canada. This unique Canadian guideline model is globally recognized, and will also be launched in the UK, with further editions being planned for Asia and the Caribbean. For more information, visit www.mumshealth.com.
“The impetus behind the development of the Men’s Health Guidelines for Family Medicine was an identified need for Canadian healthcare providers to learn more and provide them with the necessary tools to better treat their patients, including the 8 million Canadian men over 40 who are under their care,” said Dr. David Greenberg, MD and President, CSSAM. “These Guidelines address some conditions specific to men that other currently available resources do not.”
“June 12, 2017 is Men’s Health Week in Canada, an opportunity for healthcare providers to raise awareness of preventable health problems, and encourage early detection and treatment of disease among men,” said Tom Rossi, President and Chief Executive Officer of Acerus Pharma. “We are thrilled to provide these evidence-based Guidelines to Canadian family physicians, in partnership with the Canadian Men’s Health Foundation, as this is an important part of our commitment to advancing men’s health.”
Acerus Pharmaceuticals Corporation is a fully-integrated, Canadian specialty pharmaceutical company engaged in the development, manufacture, marketing and distribution of innovative, branded products in Men’s and Women’s Health. Acerus’ shares trade on TSX under the symbol ASP. For more information, visit www.aceruspharma.com and follow us on Twitter and LinkedIn.
Notice regarding forward-looking statements
Information in this press release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the company is subject to a number of risks and uncertainties, and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our annual information form dated March 7, 2017 that is available at www.sedar.com. Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities law.